BioSante 8K for April 20, 2007
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
__________________
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
__________________
Date
of
Report (Date of earliest event reported):
April
20, 2007
BIOSANTE
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
001-31812
|
58-2301143
|
|
(State
or Other Jurisdiction of Incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification Number)
|
|
111
Barclay Boulevard
Lincolnshire,
Illinois
|
60069
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(847)
478-0500
(Registrant’s
Telephone Number, Including Area Code)
N/A
(Former
Name or Former Address, If Changed Since Last Report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
| £ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
| £ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
| £ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
| £ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
Section
5 - Corporate Governance and Management
Item
5.02. Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
(b)
On
April 20, 2007, the Nominating and Corporate Governance Committee of the Board
of Directors of BioSante Pharmaceuticals, Inc. met to recommend to the Board
a
slate of director nominees to stand for election at BioSante’s Annual Meeting of
Stockholders scheduled for June 14, 2007. During the meeting of the Committee,
Victor Morgenstern, a current director of BioSante, notified the Committee
that
he has chosen not to stand for re-election to the Board of Directors of BioSante
at the next Annual Meeting of Stockholders in light of his other
responsibilities and obligations, including in particular an increased time
commitment to Valor Equity Partners, LLC, a private equity fund, in which Mr.
Morgenstern serves as Chairman and a principal. Mr. Morgenstern will continue
to
serve the remainder of his term as a director of BioSante and a member of the
Compensation Committee and Nominating and Corporate Governance Committee of
the
Board of Directors until the next Annual Meeting of Stockholders, which is
scheduled to be held on June 14, 2007. The Board of Directors of BioSante,
upon
recommendation of the Nominating and Corporate Governance Committee, nominated
the following six individuals to serve as directors until the next Annual
Meeting of Stockholders or until their successors are elected and qualified:
Louis W. Sullivan, M.D., Stephen M. Simes, Fred Holubow, Peter Kjaer, Ross
Mangano and Edward C. Rosenow III, M.D. All of the nominees are current members
of the Board of Directors of BioSante.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
BIOSANTE
PHARMACEUTICALS, INC.
By:
/s/
Phillip B. Donenberg
Phillip
B. Donenberg
Chief
Financial Officer, Treasurer and Secretary
Dated:
April
26,
2007